Skip to main content
italianoIT
European Commission logo print header

Nanobodies and antibodies against 2019-nCoV

Descrizione del progetto

DEENESFRITPL

Anticorpi terapeutici contro il nuovo coronavirus

Per qualsiasi malattia virale, la vaccinazione è l’unica soluzione per una protezione solida ed efficace a lungo termine e i vaccini richiedono generalmente del tempo per essere sviluppati. Tuttavia, la rapida diffusione dell’attuale pandemia di Covid-19 richiede soluzioni terapeutiche immediate. Lo scopo del progetto CoroNAb, finanziato dall’UE, è quello di identificare gli anticorpi candidati con attività neutralizzante contro il 2019-nCoV e di infonderli passivamente nei pazienti per controllare l’infezione. I ricercatori progetteranno e sintetizzeranno varianti ricombinanti di varie glicoproteine del coronavirus e le useranno per immunizzare gli animali da esperimento per generare anticorpi contro il virus. I dati sull’efficacia antivirale di questi anticorpi saranno inseriti in modelli computazionali per prevedere l’esito dell’intervento.

Obiettivo

Overview:
As of Feb 12th, 2020, the death toll of the 2019-nCoV (COVID-19) epidemic has surpassed 1000, rapidly eclipsing the total mortality of SARS. It has a current death rate estimate of around 2 deaths per 100 confirmed infections, is experiencing phenomenal growth in mainland China, and has the potential to spread globally over the coming months. While a vaccine may be useful for future epidemics of a similar virus, it is not clear that such a vaccine can be produced at a speed and scale sufficient to impact the current epidemic.

Objective:
Antibodies form the basis of a robust adaptive immune response to viral disease. Nearly all licensed vaccines mediate protection through the activity of antibodies and where vaccines are not available, passive infusion of monoclonal antibodies can fill the gap and control the infection. The overarching goal of the CoroNAb consortium is to rapidly identify, validate, and disseminate pre-clinical protein therapeutic candidates with neutralizing activity against 2019-nCoV, and to recommend where their use would be maximally effective.

Expected results:
Over the course of the project, we expect to design and synthesize recombinant variants of nCoV glycoproteins for immunization in mice, alpacas and macaques in order to generate and characterize multiple nCoV-neutralizing antibodies and nanobodies. We will develop efficient assays for the testing of such antibodies and exploit novel computational workflows to improve neutralizing antibody potency. Finally, we will employ mathematical modeling of the 2019-nCoV epidemic for forecasting intervention effectiveness.

Timeline:
We expect the project to deliver a number of nCoV neutralizing anti- and nanobodies of increasing potency over a 2 year period from start date.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

H2020-SC1-PHE-CORONAVIRUS-2020

Vedi altri progetti per questo bando

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

KAROLINSKA INSTITUTET
Contribution nette de l'UE
€ 1 816 858,75
Indirizzo
Nobels Vag 5
17177 Stockholm
Svezia

Mostra sulla mappa
Regione
Östra Sverige Stockholm Stockholms län
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 1 816 858,75

Partecipanti (3)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 30 Giugno 2023

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/101003653/it

European Union, 2024